Cotinga Pharmaceuticals Inc (COT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cotinga Pharmaceuticals Inc (COT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12405
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:59
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cotinga Pharmaceuticals Inc (Cotinga), formerly Critical Outcome Technologies Inc, is a developer of targeted therapeutics with focus on oncology. The company offers pipeline products such as COTI-2 targeting p53 and COTI-259 targeting KRAS. Its research includes program, indication, screening, lead identification, preclinical, among others. Cotinga’s COTI-2 is a novel small molecule activator of misfolded mutant p53 proteins for the treatment of ovarian and other gynecological cancers. It also offers treatment for small cell lung cancer and other products for Alzheimer’s disease, HIV integrase inhibitors, and multiple sclerosis. The company uses its proprietary technology Chemsas, a multistage computational platform technology based on hybrid of machine learning technologies and proprietary algorithms which allows accurate prediction of biological activity from the molecular structure. It serves pharmaceutical and biotechnology companies. Cotinga is headquartered in Boston, Massachusetts, the US.

Cotinga Pharmaceuticals Inc (COT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Critical Outcome Technologies And Portage Biotech To Form Joint Venture 12
Critical Outcome Technologies Enters Into Drug Discovery Agreement With Global Pharma Company 14
Critical Outcome Technologies Enters Into Agreement With Delmar Chemicals To Develop New Drug Candidates 15
Critical Outcome Technologies Enters Into Collaboration Agreement With University of Western Ontario 16
Equity Offering 17
Cotinga Pharma Raises USD1.6 Million in Private Placement of Shares and Warrants 17
Critical Outcome Technologies Raises USD0.4 Million in Second Tranche of Private Placement of Units 18
Critical Outcome Technologies Raises USD1.2 Million in First Tranche of Private Placement of Units 19
Critical Outcome Technologies Raises USD1.2 Million in Private Placement of Shares upon Exercise of Warrants 20
Critical Outcome Technologies Raises USD1 Million in Private Placement of Shares upon Exercise of Warrants 21
Critical Outcome Technologies Raises USD1 Million in Private Placement of Units 22
Critical Outcome Technologies Raises USD1 Million in Private Placement of Shares Upon Exercise of Warrants 23
Critical Outcome Raises USD0.6 Million in Second Tranche of Private Placement of Shares 24
Critical Outcome Raises USD0.36 Million in First Tranche of Private Placement of Shares 25
Critical Outcome Raises USD0.4 Million in Private Placement of Units 26
Critical Outcome Raises USD0.22 Million in Private Placement of Units 27
Critical Outcome Technologies Raises USD0.6 Million in Third Tranche of Private Placement of Units 28
Critical Outcome Technologies Completes Private Placement Of Units For US$0.1 Million 30
Critical Outcome Technologies Completes Third Tranche Of Private Placement Of Units For US$0.12 Million 31
Critical Outcome Technologies Completes Second Tranche of Private Placement of Units for USD0.2 Million 33
Critical Outcome Technologies Completes Private Placement Of Units For US$0.5 Million 34
Critical Outcome Technologies Completes Final Tranche Of Private Placement Of Units For US$0.3 Million 35
Debt Offering 36
Critical Outcome Technologies Completes Private Placement Of Debentures For US$0.4 Million 36
Cotinga Pharmaceuticals Inc – Key Competitors 38
Cotinga Pharmaceuticals Inc – Key Employees 39
Cotinga Pharmaceuticals Inc – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Financial Announcements 41
Oct 02, 2018: Cotinga Pharmaceuticals reports fiscal 2019 first quarter financial and operating results 41
Aug 29, 2018: Cotinga Pharmaceuticals reports fiscal 2018 fourth quarter and full year financial and operating results 43
Apr 03, 2018: Cotinga Pharmaceuticals Reports Fiscal 2018 Third Quarter Financial and Operating Results 45
Dec 29, 2017: Critical Outcome Technologies Reports Fiscal 2018 Second Quarter Financial and Operating Results 47
Sep 29, 2017: Critical Outcome Technologies Reports Fiscal 2018 First Quarter Financial and Operating Results 49
Aug 28, 2017: Critical Outcome Technologies Announces Fourth Quarter and Full Year 2017 Financial Results 51
Mar 16, 2017: Critical Outcome Technologies Reports Third Quarter Financial and Operating Results for Fiscal Year 2017 53
Corporate Communications 54
Jul 02, 2018: Cotinga Pharmaceuticals announces management and board changes 54
May 11, 2017: Critical Outcome Technologies Appoints Experienced Biotech Leader as Chief Scientific Officer 55
Feb 01, 2017: Critical Outcome Technologies Announces Departure of Chief Scientific Officer 56
Other Significant Developments 57
Jan 08, 2018: Critical Outcome Technologies Changes Name to Cotinga Pharmaceuticals 57
Dec 21, 2017: Critical Outcome Technologies Provides Scientific and Business Update at Annual General Meeting and Announces Approval of Name Change 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cotinga Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Critical Outcome Technologies And Portage Biotech To Form Joint Venture 12
Critical Outcome Technologies Enters Into Drug Discovery Agreement With Global Pharma Company 14
Critical Outcome Technologies Enters Into Agreement With Delmar Chemicals To Develop New Drug Candidates 15
Critical Outcome Technologies Enters Into Collaboration Agreement With University of Western Ontario 16
Cotinga Pharma Raises USD1.6 Million in Private Placement of Shares and Warrants 17
Critical Outcome Technologies Raises USD0.4 Million in Second Tranche of Private Placement of Units 18
Critical Outcome Technologies Raises USD1.2 Million in First Tranche of Private Placement of Units 19
Critical Outcome Technologies Raises USD1.2 Million in Private Placement of Shares upon Exercise of Warrants 20
Critical Outcome Technologies Raises USD1 Million in Private Placement of Shares upon Exercise of Warrants 21
Critical Outcome Technologies Raises USD1 Million in Private Placement of Units 22
Critical Outcome Technologies Raises USD1 Million in Private Placement of Shares Upon Exercise of Warrants 23
Critical Outcome Raises USD0.6 Million in Second Tranche of Private Placement of Shares 24
Critical Outcome Raises USD0.36 Million in First Tranche of Private Placement of Shares 25
Critical Outcome Raises USD0.4 Million in Private Placement of Units 26
Critical Outcome Raises USD0.22 Million in Private Placement of Units 27
Critical Outcome Technologies Raises USD0.6 Million in Third Tranche of Private Placement of Units 28
Critical Outcome Technologies Completes Private Placement Of Units For US$0.1 Million 30
Critical Outcome Technologies Completes Third Tranche Of Private Placement Of Units For US$0.12 Million 31
Critical Outcome Technologies Completes Second Tranche of Private Placement of Units for USD0.2 Million 33
Critical Outcome Technologies Completes Private Placement Of Units For US$0.5 Million 34
Critical Outcome Technologies Completes Final Tranche Of Private Placement Of Units For US$0.3 Million 35
Critical Outcome Technologies Completes Private Placement Of Debentures For US$0.4 Million 36
Cotinga Pharmaceuticals Inc, Key Competitors 38
Cotinga Pharmaceuticals Inc, Key Employees 39
Cotinga Pharmaceuticals Inc, Other Locations 40

List of Figures
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cotinga Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Cotinga Pharmaceuticals Inc (COT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • KMG Chemicals Inc (KMG):企業の財務・戦略的SWOT分析
    KMG Chemicals Inc (KMG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Daito Trust Construction Co., Ltd.:企業の戦略・SWOT・財務情報
    Daito Trust Construction Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Daito Trust Construction Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Hitachi Capital (UK) PLC:企業の戦略・SWOT・財務情報
    Hitachi Capital (UK) PLC - Strategy, SWOT and Corporate Finance Report Summary Hitachi Capital (UK) PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Cardiva Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Cardiva Medical Inc (Cardiva) designs, develops and commercializes of vascular access management products. The major products of the company include VASCADE vascular closure system (VCS) for femoral arterial access site closure post-diagnostic and interventional endovascular procedures; and …
  • Applied Materials Inc (AMAT):企業の財務・戦略的SWOT分析
    Applied Materials Inc (AMAT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • United States Steel Corp (X):企業の財務・戦略的SWOT分析
    United States Steel Corp (X) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • U.S. Stem Cell Inc (USRM):企業の財務・戦略的SWOT分析
    U.S. Stem Cell Inc (USRM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Cymbet Corp:電力:M&Aディール及び事業提携情報
    Summary Cymbet Corp (Cymbet) is a clean technology company that offers energy storage solutions for microelectronic systems. The company’s products include EnerChip, EnerChip solid state batteries, EnerChip bare die, EnerChip RTC and evaluation kits. Its devices offers new concept in energy storage …
  • Enterprise Holdings, Inc.:企業の戦略・SWOT・財務情報
    Enterprise Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Enterprise Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Banque Marocaine du Commerce Exterieur SA:企業の戦略・SWOT・財務分析
    Banque Marocaine du Commerce Exterieur SA - Strategy, SWOT and Corporate Finance Report Summary Banque Marocaine du Commerce Exterieur SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Compania General de Combustibles SA:石油・ガス:M&Aディール及び事業提携情報
    Summary Compania General de Combustibles SA (CGC), a subsidiary of Corporacion America Sudamericana SA is an oil and gas company that produces petroleum products. The company’s products include crude oil, liquefied petroleum gas, natural gas, gasoline and others. It offers services such as domestic …
  • CPC Corp:企業の戦略的SWOT分析
    CPC Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • National Heart Lung and Blood Institute-製薬・医療分野:企業M&A・提携分析
    Summary National Heart Lung and Blood Institute (NHLBI), a subsidiary of National Institutes of Health is a medical research institute that provides treatment for heart, lung, and blood diseases.The institute conducts research studies with patients who have diseases of heart and blood vessels, lungs …
  • C&S Wholesale Grocers, Inc.
    C&S Wholesale Grocers, Inc. - Strategy, SWOT and Corporate Finance Report Summary C&S Wholesale Grocers, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • SIGVARIS Management AG:企業の戦略的SWOT分析
    SIGVARIS Management AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • NetScout Systems, Inc. (NTCT):企業の財務・戦略的SWOT分析
    NetScout Systems, Inc. (NTCT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Kier Group Plc (KIE):電力:M&Aディール及び事業提携情報
    Summary Kier Group plc (Kier) is a construction and property development company specialized in residential and commercial property development, and infrastructure project investment. The company’s services portfolio include construction and civil engineering, support services, property development, …
  • AorTech International Plc (AOR):企業の財務・戦略的SWOT分析
    AorTech International Plc (AOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Valence Health-製薬・医療分野:企業M&A・提携分析
    Summary Valence Health is a healthcare company that provides healthcare services. The company offers solutions such as consulting, vision platform, quality measurement, cost and utilization, data collection, contract administration, managed services, and actuarial services. It provides health care s …
  • ImmunoGen Inc (IMGN):企業の財務・戦略的SWOT分析
    ImmunoGen Inc (IMGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆